Nuvectis Pharma, Inc./$NVCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nuvectis Pharma, Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- Ticker
- $NVCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- Fort Lee, United States
- Website
- www.nuvectis.com
NVCT Metrics
BasicAdvanced
$642M
-
-$1.30
-0.26
-
Price and volume
Market cap
$642M
Beta
-0.26
52-week high
$29.28
52-week low
$5.55
Average daily volume
196K
Financial strength
Current ratio
1.683
Quick ratio
1.667
Profitability
Management effectiveness
Return on assets (TTM)
-73.07%
Return on equity (TTM)
-214.58%
Valuation
Price to book
57.88
Price to tangible book (TTM)
57.88
Price to free cash flow (TTM)
-23.422
Free cash flow yield (TTM)
-4.27%
Free cash flow per share (TTM)
-0.841
Growth
Earnings per share change (TTM)
12.77%
3-year earnings per share growth (CAGR)
-5.07%
Bulls say / Bears say
Haisco’s ciprocopan (NXP100) was approved in China for treatment-naive PNH patients, making it the first once-daily oral Factor B inhibitor to receive global approval. That provides clinical and regulatory validation for Nuvectis’s licensed rights outside China, though those markets still need their own approvals. (GlobeNewswire)
NXP200 received Breakthrough Therapy Designation in China for BRAF V600-mutant recurrent or progressive high-grade glioma, and Nuvectis says it is preparing a US IND submission for the fourth quarter of 2026. The designation and reported clinical activity offer a meaningful catalyst for the company’s oncology pipeline. (GlobeNewswire)
Nuvectis raised $115 million in a July follow-on offering and said the proceeds extend its cash runway into the first half of 2029. That gives it more time to advance NXP100 and its oncology programmes without an immediate need for further financing. (GlobeNewswire)
The China approval for NXP100 does not establish that it will succeed in the US: Nuvectis said a pre-IND meeting and US IND submission were still expected in the fourth quarter of 2026. Its ex-China opportunity therefore still depends on further regulatory and clinical progress. (GlobeNewswire)
The Haisco deal requires a $20 million upfront payment, up to $20 million in early development milestones and up to about $1.4 billion in further milestones, plus tiered royalties. Those obligations could absorb substantial value if the programmes advance, before accounting for Nuvectis’s own development and launch costs. (GlobeNewswire)
The July equity offering raised $115 million but diluted existing shareholders: reported shares outstanding rose from 26.7 million at the end of June to about 32.6 million by the end of July. Further funding needs could bring additional dilution if development costs exceed the company’s plans. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
NVCT Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
NVCT News
AllArticlesVideos
Funds containing NVCT
AllEURGBP
Fund name | Fund size | $NVCT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.